Refine
Document Type
- Article (13)
Language
- English (13)
Has Fulltext
- yes (13)
Is part of the Bibliography
- no (13)
Keywords
- lipocalin-2 (4)
- macrophage polarization (4)
- iron (3)
- iron metabolism (3)
- standardization (2)
- tumor progression (2)
- Breast cancer (1)
- Breast tumors (1)
- CLP (1)
- FX06 (1)
- Gene expression (1)
- Immune cells (1)
- Macrophages (1)
- Messenger RNA (1)
- RNA extraction (1)
- RNA isolation (1)
- T cells (1)
- angiogenesis (1)
- apoptosis (1)
- cancer cell metabolism (1)
- chelation therapy (1)
- clinical pathways (1)
- cross-linking (1)
- disordered iron metabolism (1)
- ectosomes (1)
- endothelial activation (1)
- exosomes (1)
- extracellular vesicles (1)
- ferroportin (1)
- gastric surgery (1)
- guidelines (1)
- hypoxia (1)
- iron chelator (1)
- iron chelators (1)
- iron homeostasis (1)
- iron-trafficking (1)
- macrophage (1)
- macrophages (1)
- microparticles (1)
- microvesicles (1)
- minimal information requirements (1)
- oncological gastrectomy (1)
- outcomes (1)
- phagocytosis (1)
- polymeric micelle (1)
- polypept(o)ide (1)
- primary mouse proximal tubular cells (1)
- quality of care (1)
- renal cell carcinoma (1)
- renal ischemia reperfusion injury (1)
- renal tubular epithelial cells (1)
- reproducibility (1)
- rigor (1)
- sphingosine-1-phosphate (1)
- superparamagnetic iron oxide nanoparticles (1)
- tubular regeneration (1)
- tumor microenvironment (1)
- tumor stroma (1)
- tumor-associated macrophages (1)
- tumor-associated macrophages (TAM) (1)
Institute
A growing body of evidence suggests that macrophage polarization dictates the expression of iron-regulated genes. Polarization towards iron sequestration depletes the microenvironment, whereby extracellular pathogen growth is limited and inflammation is fostered. In contrast, iron release contributes to cell proliferation, which is important for tissue regeneration. Moreover, macrophages constitute a major component of the infiltrates in most solid tumors. Considering the pivotal role of macrophages for iron homeostasis and their presence in association with poor clinical prognosis in tumors, we approached the possibility to target macrophages with intracellular iron chelators. Analyzing the expression of iron-regulated genes at mRNA and protein level in primary human macrophages, we found that the iron-release phenotype is a characteristic of polarized macrophages that, in turn, stimulate tumor cell growth and progression. The application of the intracellular iron chelator (TC3-S)2 shifted the macrophage phenotype from iron release towards sequestration, as determined by the iron-gene profile and atomic absorption spectroscopy (AAS). Moreover, whereas the addition of macrophage supernatants to tumor cells induced tumor growth and metastatic behavior, the supernatant of chelator-treated macrophages reversed this effect. Iron chelators demonstrated potent anti-neoplastic properties in a number of cancers, both in cell culture and in clinical trials. Our results suggest that iron chelation could affect not only cancer cells but also the tumor microenvironment by altering the iron-release phenotype of tumor-associated macrophages (TAMs). The study of iron chelators in conjunction with the effect of TAMs on tumor growth could lead to an improved understanding of the role of iron in cancer biology and to novel therapeutic avenues for iron chelation approaches.
Iron is an essential co-factor for cellular processes. In the immune system, it can activate macrophages and represents a potential therapeutic for various diseases. To specifically deliver iron to macrophages, iron oxide nanoparticles are embedded in polymeric micelles of reactive polysarcosine-block-poly(S-ethylsulfonyl-l-cysteine). Upon surface functionalization via dihydrolipoic acid, iron oxide cores act as crosslinker themselves and undergo chemoselective disulfide bond formation with the surrounding poly(S-ethylsulfonyl-l-cysteine) block, yielding glutathione-responsive core cross-linked polymeric micelles (CCPMs). When applied to primary murine and human macrophages, these nanoparticles display preferential uptake, sustained intracellular iron release, and induce a strong inflammatory response. This response is also demonstrated in vivo when nanoparticles are intratracheally administered to wild-type C57Bl/6N mice. Most importantly, the controlled release concept to deliver iron oxide in redox-responsive CCPMs induces significantly stronger macrophage activation than any other iron source at identical iron levels (e.g., Feraheme), directing to a new class of immune therapeutics.
(1) Background: Oncological gastrectomy requires complex multidisciplinary management. Clinical pathways (CPs) can potentially facilitate this task, but evidence related to their use in managing oncological gastrectomy is limited. This study evaluated the effect of a CP for oncological gastrectomy on process and outcome quality. (2) Methods: Consecutive patients undergoing oncological gastrectomy before (n = 64) or after (n = 62) the introduction of a CP were evaluated. Assessed parameters included catheter and drain management, postoperative mobilization, resumption of diet and length of stay. Morbidity, mortality, reoperation and readmission rates were used as indicators of outcome quality. (3) Results: Enteral nutrition was initiated significantly earlier after CP implementation (5.0 vs. 7.0 days, p < 0.0001). Readmission was more frequent before CP implementation (7.8% vs. 0.0%, p = 0.05). Incentive spirometer usage increased following CP implementation (100% vs. 90.6%, p = 0.11). Mortality, morbidity and reoperation rates remained unchanged. (4) Conclusions: After implementation of an oncological gastrectomy CP, process quality improved, while indicators of outcome quality such as mortality and reoperation rates remained unchanged. CPs are a promising tool to standardize perioperative care for oncological gastrectomy